The present invention relates to compounds of Formula I,
wherein R
1
, R
2
, R
3
, R
4
, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.